Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Regulatory & Competitive Sport Status FDA Position PT-141 received FDA approval in June 2019 but with significant restrictions: Approved as Vyleesi (bremelanotide injection) for one specific indication only Contraindicated in patients with uncontrolled hypertension or cardiovascular disease due to transient blood pressure effects Prescribing guidelines limit use to maximum one dose per 24 hours and eight doses per month Discontinuation recommended after 8 weeks if no improvement observed No approved use in men despite off-label prescribing by some physicians The FDA designation as a first-in-class medication reflects its novel mechanism but also indicates limited clinical experience compared to established drug classes
Care must be taken to dissolve the powder completely without vigorous shaking, which can denature the peptide structure
Findings from a new study suggest that vitamin D supplementation reduces the risk of developing vertigo in people who are deficient
"Entrez Gene: GSTA1 glutathione S-transferase A1"
Hepatology 63 , 731744 (2016)
Rapid Phytosynthesis of Silver Nanoparticles Using Chlorophytum Borivilianum Root Extract and its Antimicrobial Activity
US$ 28.92
US$ 22.29
US$ 28.69
US$ 28.96
US$ 22.25
US$ 22.06
US$ 22.41
